Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2024 17:39 ET | Source: Opthea Limited

Opthea Appoints Sujal Shah to the Board of Directors

MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
March 19, 2024 06:00 ET | Source: Opthea Limited

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to...
March 05, 2024 17:08 ET | Source: Opthea Limited

Opthea to Participate in the Leerink Partners Global Biopharma Conference

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
February 28, 2024 17:55 ET | Source: Opthea Limited

Opthea Reports Half-Year Financial Results and Business Updates

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....
February 19, 2024 18:25 ET | Source: Opthea Limited

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
February 14, 2024 07:00 ET | Source: Opthea Limited

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 ...
February 01, 2024 06:00 ET | Source: Opthea Limited

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology...
December 27, 2023 06:00 ET | Source: Opthea Limited

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended...
December 19, 2023 06:00 ET | Source: Opthea Limited

Opthea Receives A$8.8 million R&D Tax Incentive

MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
December 01, 2023 05:30 ET | Source: Opthea Limited

Opthea to Present at the FLORetina 2023 Congress

MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...